Liver–Intestine-Cadherin Is a Sensitive Marker of Intestinal Differentiation During Barrett’s Carcinogenesis
Histopathologic differentiation between the stages of Barrett’s carcinogenesis is often challenging. Liver–intestine (LI)-cadherin, an intestine-specific marker, is involved in intestinal metaplasia development in gastric and colon cancers and could be of value in diagnosis and differentiation.
To examine the expression of LI-cadherin in the sequence of Barrett’s carcinogenesis and to evaluate its association with clinicopathological data.
LI-cadherin expression was immunohistologically investigated, by use of anti-CDH17 antibody, in gastric mucosa (GM) biopsies taken from the cardia (n = 9), in Barrett’s esophagus (BE) without intraepithelial neoplasia (without IEN) (n = 9) and BE with low-grade IEN (n = 11), and in esophageal adenocarcinoma (ADC) (n = 13).
The immunoreactivity score was highest in adenocarcinoma (mean IRS = 4.0), and dropped gradually from BE with IEN and BE without IEN (mean IRS = 2.0) to cardia mucosa (IRS = 0). Similarly, the intensity of staining and the percentage of positive cells increased during the sequential stages of BE carcinogenesis. Comparative analysis showed that LI-cadherin expression was significantly different between cardiac epithelium and ADC. Also, percentage of positive cells in GM was significantly different from that in BE with IEN. LI-cadherin IRS was lower for tumors with poor differentiation than for moderately differentiated tumors, but the difference was not statistically significant.
LI-cadherin is a sensitive marker of intestinal metaplasia and can be helpful for early histologic diagnosis of Barrett’s esophagus; it is, however, not significantly different between BE with and without IEN, and cannot be used to distinguish between these.
- Holmes RS, Vaughan TL. Epidemiology and pathogenesis of esophageal cancer. Semin Radiat Oncol. 2007;17:2–9. CrossRef
- Brown LM, Devesa SS. Epidemiologic trends in esophageal and gastric cancer in the United States. Surg Oncol Clin North Am. 2002;11:235–256. CrossRef
- Kerkhof M, van Dekken H, Steyerberg EW, et al. CYBAR study group. Grading of dysplasia in Barrett’s oesophagus: substantial interobserver variation between general and gastrointestinal pathologists. Histopathology. 2007;50:920–927. CrossRef
- Sampliner RE. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett’s esophagus. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol. 1998;93:1028–1032. CrossRef
- Wang KK, Sampliner RE. Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett’s esophagus. Am J Gastroenterol. 2008;103:788–797. CrossRef
- Playford RJ. New British society of gastroenterology (BSG) guidelines for the diagnosis and management of Barrett’s oesophagus. Gut. 2006;55:442. CrossRef
- Takubo K, Vieth M, Aida J, et al. Differences in the definitions used for esophageal and gastric diseases in different countries: endoscopic definition of the esophagogastric junction, the precursor of Barrett’s adenocarcinoma, the definition of Barrett’s esophagus, and histologic criteria for mucosal adenocarcinoma or high-grade dysplasia. Digestion. 2009;80:248–257. CrossRef
- Takubo K, Aida J, Naomoto Y, et al. Cardiac rather than intestinal type background in endoscopic specimens of minute Barrett adenocarcinoma. Hum Pathol. 2009;40:65–74. CrossRef
- Liu W, Hahn H, Odze RD, et al. Metaplastic esophageal columnar epithelium without goblet cells shows DNA content abnormalities similar to goblet cell-containing epithelium. Am J Gastroenterol. 2009;104:816–824. CrossRef
- Ranscht B. Cadherins and catenins: interactions and functions in embryogenic development. Curr Opin Cell Biol. 1994;6:740–746. CrossRef
- Takeichi M. Morphogenetic roles of classic cadherins. Curr Opin Cell Biol. 1995;7:619–627. CrossRef
- Hirohashi S. Inactivation of the E-cadherin-mediated cell adhesion system in human cancers. Am J Pathol. 1998;153:333–339. CrossRef
- Okegawa T, Pong RC, Li Y, et al. The role of cell adhesion molecule in cancer progression and its application in cancer therapy. Acta Biochim Pol. 2004;51:445–457.
- Cavallaro U, Christofori G. Cell adhesion in tumor invasion and metastasis: loss of the glue is not enough. Biochim Biophys Act. 2001;1552:39–45.
- Berndorff D, Gessner R, Kreft B, et al. Liver-intestine cadherin: molecular cloning and characterization of a novel Ca2+-dependent cell adhesion molecule expressed in liver and intestine. J Cell Biol. 1994;125:1353–1369. CrossRef
- Gessner R, Tauber R. Intestinal cell adhesion molecules. Liver-intestine cadherin. Ann NY Acad Sci. 2000;915:136–143. CrossRef
- Grotzinger C, Kneifel J, Patschan D, et al. LI-cadherin: a marker of gastric metaplasia and neoplasia. Gut. 2001;49:73–81. CrossRef
- Wong BW, Luk JM, Ng IO, et al. Identification of liver-intestine cadherin in hepatocellular carcinoma—a potential disease marker. Biochem Biophys Res Commun. 2003;311:618–624. CrossRef
- Takamura M, Sakamoto M, Ino Y, et al. Expression of liver-intestine cadherin and its possible interaction with galectin-3 in ductal adenocarcinoma of the pancreas. Cancer Sci. 2003;94:425–430. CrossRef
- Freund JN, Domon-Dell C, Kedinger M, et al. The Cdx-1 and Cdx-2 homeobox genes in the intestine. Biochem Cell Biol. 1998;76:957–969.
- Colleypriest BJ, Farrant JM, Slack JM, et al. The role of Cdx2 in Barrett’s metaplasia. Biochem Soc Trans. 2010;38:364–369. CrossRef
- Souza RF, Krishnan K, Spechler SJ. Acid, bile, and CDX: the ABCs of making Barrett’s metaplasia. Am J Physiol Gastrointest Liver Physiol. 2008;295:G211–G218. CrossRef
- Remmele W, Stegner HE. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe. 1987;8:138–140.
- Weimann A, Zimmermann M, Gross M, et al. CDX2 and LI-cadherin expression in esophageal mucosa: use of both markers can facilitate the histologic diagnosis of Barrett’s esophagus and carcinoma. Int J Surg Pathol. 2010;18:330–337.
- Weimann A, Rieger A, Zimmermann M, et al. Comparison of six immunohistochemical markers for the histologic diagnosis of neoplasia in Barrett’s esophagus. Virchows Arch. 2010;457:537–545. CrossRef
- Takamura M, Yamagiwa S, Wakai T, et al. Loss of liver-intestine cadherin in human intrahepatic cholangiocarcinoma promotes angiogenesis by up-regulating metal-responsive transcription factor-1 and placental growth factor. Int J Oncol. 2010;36:245–254.
- Dong W, Yu Q, Xu Y. Altered expression of a Li-cadherin in gastric cancer and intestinal metaplasia. Dig Dis Sci. 2007;52:536–542. CrossRef
- Ko S, Chu KM, Luk JM, et al. CDX2 co-localizes with liver-intestine cadherin in intestinal metaplasia and adenocarcinoma of the stomach. J Pathol. 2005;205:615–622. CrossRef
- Yamada KM, Geiger B. Molecular interactions in cell adhesion complexes. Curr Opin Cell Biol. 1997;9:76–85. CrossRef
- Ahmad A, Hart IR. Mechanisms of metastasis. Crit Rev Oncol Hematol. 1997;26:163–173. CrossRef
- Hinoi T, Lucas PC, Kuick R, et al. CDX2 regulates liver intestine-cadherin expression in normal and malignant colon epithelium and intestinal metaplasia. Gastroenterology. 2002;123:1565–1577. CrossRef
- Eda A, Osawa H, Satoh K, et al. Aberrant expression of CDX2 in Barrett’s epithelium and inflammatory esophageal mucosa. J Gastroenterol. 2003;38:14–22. CrossRef
- Dong WG, Yu QF, Xu Y, et al. Li-cadherin is inversely correlated with galectin-3 expression in gastric cancer. Dig Dis Sci. 2008;53:1811–1817. CrossRef
- Liver–Intestine-Cadherin Is a Sensitive Marker of Intestinal Differentiation During Barrett’s Carcinogenesis
- Open Access
- Available under Open Access This content is freely available online to anyone, anywhere at any time.
Digestive Diseases and Sciences
Volume 58, Issue 3 , pp 699-705
- Cover Date
- Print ISSN
- Online ISSN
- Springer US
- Additional Links
- Barrett’s esophagus
- Esophageal adenocarcinoma
- Intestinal metaplasia
- Intraepithelial neoplasia
- Industry Sectors
- Author Affiliations
- 1. Department of Digestive Tract Diseases, Medical University of Lodz, Str. Kopcinskiego 22, 90-153, Lodz, Poland
- 2. Institute of Pathology, Klinikum Bayreuth, Preuschwitzer Str. 101, 95445, Bayreuth, Germany
- 3. Department of Pathology, Chair of Oncology, Medical University of Lodz, Str. Pomorska 251, 92-213, Lodz, Poland
- 4. Department of Chest Surgery and Respiratory Rehabilitation, Medical University of Lodz, Str. Pabianicka 62, 93-513, Lodz, Poland
- 5. Institute of Pathology, University of Erlangen-Nurnberg, Krankenhausstraße 8-10, Erlangen, Germany